CLINICAL TRIALS PROFILE FOR MARIMASTAT

Clinical Trials for Marimastat

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00002911 ↗	Marimastat in Treating Patients With Stage III Non-small Cell Lung Cancer	Completed	ILEX Oncology Services, Incorporated	Phase 3	RATIONALE: Marimastat may stop the growth of non-small cell lung cancer by stopping blood flow to the tumor. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of marimastat in treating patients who have residual stage III non-small cell lung cancer.
NCT00003010 ↗	Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy	Completed	National Cancer Institute (NCI)	Phase 3	RATIONALE: Marimastat may stop the growth of breast cancer by stopping blood flow to the tumor. It is not known whether chemotherapy is more effective with or without marimastat for breast cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of marimastat with that of no further therapy in treating women who have metastatic breast cancer that is responding or stable after chemotherapy.
NCT00003010 ↗	Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy	Completed	North Central Cancer Treatment Group	Phase 3	RATIONALE: Marimastat may stop the growth of breast cancer by stopping blood flow to the tumor. It is not known whether chemotherapy is more effective with or without marimastat for breast cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of marimastat with that of no further therapy in treating women who have metastatic breast cancer that is responding or stable after chemotherapy.
NCT00003010 ↗	Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy	Completed	Eastern Cooperative Oncology Group	Phase 3	RATIONALE: Marimastat may stop the growth of breast cancer by stopping blood flow to the tumor. It is not known whether chemotherapy is more effective with or without marimastat for breast cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of marimastat with that of no further therapy in treating women who have metastatic breast cancer that is responding or stable after chemotherapy.
NCT00003011 ↗	Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer	Completed	NCIC Clinical Trials Group	Phase 3	RATIONALE: Marimastat may stop the growth of lung cancer by stopping blood flow to the tumor. It is not yet known if marimastat is an effective treatment for small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of marimastat with a placebo following chemotherapy in treating patients who have small cell lung cancer.
NCT00261391 ↗	Phase I Drug Trial for S/E of Marimastat in Disabling Malformations When no Other Options.	Completed	Boston Children's Hospital	Phase 1	3 patients were enrolled in each of 3 study cohorts. There three cohorts were given differing, incrementally larger doses of this phase I drug. The same safety measures are being obtained on all patients. Efficacy measures were individualized as enrolllees do not have the same underlying vascular anomaly. The study is structured to include a 24 month drug-phase and a 24 month follow-up phase. The study is now closed to enrollment.
NCT00261391 ↗	Phase I Drug Trial for S/E of Marimastat in Disabling Malformations When no Other Options.	Completed	Boston Children’s Hospital	Phase 1	3 patients were enrolled in each of 3 study cohorts. There three cohorts were given differing, incrementally larger doses of this phase I drug. The same safety measures are being obtained on all patients. Efficacy measures were individualized as enrolllees do not have the same underlying vascular anomaly. The study is structured to include a 24 month drug-phase and a 24 month follow-up phase. The study is now closed to enrollment.

Clinical Trial Conditions for Marimastat

Condition Name

Condition Name for
Intervention	Trials
Lung Cancer	2
Breast Cancer	1
Vascular Anomalies	1

Condition MeSH

Condition MeSH for
Intervention	Trials
Lung Neoplasms	2
Breast Neoplasms	1
Carcinoma, Non-Small-Cell Lung	1
Vascular Malformations	1

Clinical Trial Locations for Marimastat

Trials by Country

Trials by Country for
Location	Trials
United States	35
Canada	10

Trials by US State

Trials by US State for
Location	Trials
Minnesota	2
Arizona	2
Pennsylvania	2
Ohio	2
New York	2

Clinical Trial Progress for Marimastat

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	3
Phase 1	1

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	4

Clinical Trial Sponsors for Marimastat

Sponsor Name

Sponsor Name for
Sponsor	Trials
ILEX Oncology Services, Incorporated	1
National Cancer Institute (NCI)	1
North Central Cancer Treatment Group	1

Sponsor Type

Sponsor Type for
Sponsor	Trials
Other	5
Industry	1
NIH	1